News | May 15, 2021
Cipla reports Q4FY21 consolidated net profit of Rs. 413.38 Cr
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
The facility is expected to be completed in 2024
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
Subscribe To Our Newsletter & Stay Updated
